“GEPANTS” CGPR ANTAGONIST – A NEW CLINICAL APPROACH TO TREAT MIGRAINE AND NEUROPEPTIDES
DOI:
https://doi.org/10.22159/ajpcr.2025v18i7.54791Keywords:
Migraine, CGRP antagonist, Gepants, Trigeminovascular system, FDA approved drugsAbstract
The present review is devoted to apparent part of CGRP in migraine pathogenesis and to depict the various treatment modalities that are presently available to target this neuropeptide. A veritably incapacitating neurovascular illness, migraines are typified by excruciating headaches that are accompanied by nausea, photophobia, and/or phonophobia, as well as activation of the trigeminovascular system by the production of calcitonin-gene related peptide (CGRP). Zavegepant through nasal drug delivery system is one of the best approaches which used as a target drug delivery in sustained controlled release fashion. The main advantage to choose the nasal route for drug delivery is to bypass the first hepatic metabolism and direct absorption of drug into the systemic circulation. To provide a relevant background, a brief discussion of CGRP antagonist and FDA approved drugs for migraine treatment will also be considered in this review.
Downloads
References
Villar-Martinez MD, Goadsby PJ. Pathophysiology and therapy of associated features of migraine. Cells. 2022;11(17):2767. doi: 10.3390/ cells11172767, PMID 36078174
Aguilar-Shea AL, Membrilla Md JA, Diaz-De-Teran J. Migraine review for general practice. Aten Primaria. 2022;54(2):102208. doi: 10.1016/j. aprim.2021.102208, PMID 34798397
Dodick DW. Migraine. Lancet. 2018;391(10127):1315-30. doi: 10.1016/S0140-6736(18)30478-1, PMID 29523342
Kissoon NR, Cutrer FM. Aura and other neurologic dysfunction in or with migraine. Headache. 2017;57(7):1179-94. doi: 10.1111/ head.13101, PMID 28542895
Chinthapalli K, Logan AM, Raj R, Nirmalananthan N. Assessment of acute headache in adults - what the general physician needs to know. Clin Med (Lond). 2018;18(5):422-7. doi: 10.7861/clinmedicine.18-5-422, PMID 30287441
Qubty W, Patniyot I. Migraine pathophysiology. Pediatr Neurol. 2020;107:1-6. doi: 10.1016/j.pediatrneurol.2019.12.014, PMID 32192818
Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review) [RETIRED]: Report of the quality standards subcommittee of the American academy of neurology. Neurology. 2000;55(6):754-62. doi: 10.1212/ WNL.55.6.754, PMID 10993991
Gago-Veiga AB, Vivancos J, Sobrado M. The premonitory phase: A crucial stage in migraine. Neurol (Engl Ed). 2021;36(4):298-304. doi: 10.1016/j.nrleng.2017.09.006
Dikmen PY. The acute treatment of migraine attack in adults and American headache society evidence assessment of migraine pharmacotherapies. Turk J Neurol. 2016;22(1):3-7. doi: 10.4274/ tnd.93753
Vadivelu N, Gowda AM, Urman RD, Jolly S, Kodumudi V, Maria M, et al. Ketorolac tromethamine - routes and clinical implications. Pain Pract. 2015;15(2):175-93. doi: 10.1111/papr.12198, PMID 24738596
Nurathirah MN, Yazid MB, Norhayati MN, Baharuddin KA, Abu Bakar MA. Efficacy of ketorolac in the treatment of acute migraine attack: A systematic review and meta‐analysis. Acad Emerg Med. 2022;29(9):1118-31. doi: 10.1111/acem.14457, PMID 35138658
Law S, Derry S, Moore RA. Triptans for acute cluster headache. Cochrane Database Syst Rev. 2010;(4):CD008042. doi: 10.1002/14651858. CD008042.pub2, PMID 20393964
Yang CP, Liang CS, Chang CM, Yang CC, Shih PH, Yau YC, et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: A systematic review and meta-analysis. JAMA Netw Open. 2021;4(10):e2128544. doi: 10.1001/jamanetworkopen.2021.28544, PMID 34633423
Cieszkowska J, Otręba K, Czupryńska K, Daniel P, Leśkiewicz M, Składanek JA. Diagnosis and treatment of migraine: An analysis of the latest diagnostic and therapeutic guidelines. J Educ Health Sport. 2024;74:51722. doi: 10.12775/JEHS.2024.74.51722
Cortel-LeBlanc MA, Orr SL, Dunn M, James D, Cortel-LeBlanc A. Managing and preventing migraine in the emergency department: A review. Ann Emerg Med. 2023;82(6):732-51. doi: 10.1016/j. annemergmed.2023.05.024, PMID 37436346
Ailani J. Acute migraine treatment. Continuum (Minneap Minn). 2021;27(3):597-612. doi: 10.1212/CON.0000000000000956, PMID 34048394
Dodick DW, Goadsby PJ, Schwedt TJ, Lipton RB, Liu C, Lu K, et al. Ubrogepant for the treatment of migraine attacks during the prodrome: A Phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. Lancet. 2023;402(10419):2307-16. doi: 10.1016/S0140-6736(23)01683-5, PMID 37979595
Lipton RB, Croop R, Stock DA, Madonia J, Forshaw M, Lovegren M, et al. Safety, tolerability, and efficacy of zavegepant 10 Mg nasal spray for the acute treatment of migraine in the USA: A Phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023;22(3):209-17. doi: 10.1016/S1474-4422(22)00517-8, PMID 36804093
Krege JH, Rizzoli PB, Liffick E, Doty EG, Dowsett SA, Wang J, et al. Safety findings from phase 3 lasmiditan studies for acute treatment of migraine: Results from samurai and Spartan. Cephalalgia. 2019;39(8):957-66. doi: 10.1177/0333102419855080, PMID 31166697
Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB, et al. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018;91(24):e2222-32. doi: 10.1212/ WNL.0000000000006641, PMID 30446595
Sheykhzade M, Amandi N, Pla MV, Abdolalizadeh B, Sams A, Warfvinge K, et al. Binding and functional pharmacological characteristics of gepant-type antagonists in rat brain and mesenteric arteries. Vasc Pharmacol. 2017;90:36-43. doi: 10.1016/j. vph.2017.02.001, PMID 28192258
Urits I, Gress K, Charipova K, Zamarripa AM, Patel PM, Lassiter G, et al. Pharmacological options for the treatment of chronic migraine pain. Best Pract Res Clin Anaesthesiol. 2020;34(3):383-407. doi: 10.1016/j.bpa.2020.08.002, PMID 33004155
Arulmani U, Maassenvandenbrink A, Villalón CM, Saxena PR. Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol. 2004;500(1-3):315-30. doi: 10.1016/j.ejphar.2004.07.035, PMID 15464043
Tajti J, Szok D, Majláth Z, Tuka B, Csáti A, Vécsei L. Migraine and neuropeptides. Neuropeptides. 2015;52:19-30. doi: 10.1016/j. npep.2015.03.006, PMID 26094101
Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience. 2010;169(2):683-96. doi: 10.1016/j.neuroscience.2010.05.016, PMID 20472035
Tepper SJ. Acute treatment of migraine. Neurol Clin. 2019;37(4):727-42. doi: 10.1016/j.ncl.2019.07.006, PMID 31563229
Lanteri-Minet M. What’s new in the migraine attack treatment? Rev Neurol (Paris). 2013;169(5):436-41. doi: 10.1016/j.neurol.2013.03.006, PMID 23602496
Wilbanks C. Migraine in adult primary care. J Nurse Pract. 2022;18(4):366-9. doi: 10.1016/j.nurpra.2022.01.018
Holland PR, Goadsby PJ. Targeted CGRP small molecule antagonists for acute migraine therapy. Neurotherapeutics. 2018;15(2):304-12. doi: 10.1007/s13311-018-0617-4, PMID 29556965
Ogunlaja OI, Goadsby PJ. Headache: Treatment update. eNeurologicalSci. 2022;29:100420. doi: 10.1016/j.ensci.2022.100420, PMID 36636337
Cohen F, Yuan H, DePoy EM, Silberstein SD. The arrival of anti- CGRP monoclonal antibodies in migraine. Neurotherapeutics. 2022;19(3):922-30. doi: 10.1007/s13311-022-01230-x, PMID 35426060
Lipton RB. Preventive treatment of migraine. Continuum (Minneap Minn). 2024;30(2):364-78. doi: 10.1212/CON.0000000000001418, PMID 38568488
Younis S, Latysheva NV, Danilov AB, Ashina M. CGRP receptor antagonists (gepants). Handb Clin Neurol. 2024;199:51-66. doi: 10.1016/B978-0-12-823357-3.00033-1, PMID 38307667
Mehkri Y, Hanna C, Sriram S, Lucke-Wold B, Johnson RD, Busl K. Calcitonin gene-related peptide and neurologic injury: An emerging target for headache management. Clin Neurol Neurosurg. 2022;220:107355. doi: 10.1016/j.clineuro.2022.107355, PMID 35785661
Santos-Lasaosa S, Belvís R, Cuadrado ML, Díaz-Insa S, Gago- Veiga A, Guerrero-Peral AL, et al. Calcitonin gene-related peptide in migraine: From pathophysiology to treatment. Neurol (Engl Ed). 2022;37(5):390-402. doi: 10.1016/j.nrleng.2019.03.025, PMID 35672126
Caronna E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P. CGRP monoclonal antibodies and CGRP receptor antagonists (gepants) in migraine prevention. Handb Clin Neurol. 2024;199:107-24. doi: 10.1016/B978-0-12-823357-3.00024-0, PMID 38307640
De Vries T, Boucherie DM, Van Den Bogaerdt A, Danser AH, MaassenVanDenBrink A. Blocking the CGRP receptor: Differences
across human vascular beds. Pharmaceuticals (Basel). 2023;16(8):1075. doi: 10.3390/ph16081075, PMID 37630989
Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: A double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020;19(9):727-37. doi: 10.1016/S1474-4422(20)30234-9, PMID 32822633
Khan S, Olesen A, Ashina M. CGRP, A target for preventive therapy in migraine and cluster headache: Systematic review of clinical data. Cephalalgia. 2019;39(3):374-89. doi: 10.1177/0333102417741297, PMID 29110503
Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10404):775-85. doi: 10.1016/S0140-6736(23)01049-8, PMID 37516125
Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, et al. Oral rimegepant for preventive treatment of migraine: A phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51-60. doi: 10.1016/S0140-6736(20)32544-7, PMID 33338437
Buxeraud J, Faure S. Le rimegepant (Vydura®), un nouveau medicament pour la migraine. Actual Pharm. 2024;63(635):10-2. doi: 10.1016/j. actpha.2024.02.005
Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: A randomised, Phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-45. doi: 10.1016/S0140-6736(19)31606-X, PMID 31311674
Yu S, Kim BK, Guo A, Kim MH, Zhang M, Wang Z, et al. Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: A phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2023;22(6):476-84. doi: 10.1016/S1474-4422(23)00126-6, PMID 37210098
Zavegepant hydrochloride. Am J Health Syst Pharm. 2023;80(18):1199- 200. doi: 10.1093/ajhp/zxad145, PMID 37471249
Dhillon S. Zavegepant: First approval. Drugs. 2023;83(9):825-31. doi: 10.1007/s40265-023-01885-6, PMID 37227596
Ahmed U, Saleem MM, Osman MA, Shamat SF. Novel FDA-approved zavegepant drug for treating migraine. Ann Med Surg (Lond). 2024;86(2):923-5. doi: 10.1097/MS9.0000000000001620, PMID 38333255
Larik MO, Iftekhar MA, Syed BU, Ansari O, Ansari M. Nasal spray (zavegepant) for migraines: A mini-review. Ann Med Surg (Lond). 2023;85(6):2787-90. doi: 10.1097/MS9.0000000000000843, PMID 37363553
Cipolla F, Capi M, Lionetto L, De Bernardini D, De Angelis V, Martelletti P. Zavegepant: Calcitonin gene-related peptide (CGRP) receptor antagonist, treatment of migraine. Drugs Future. 2021;46(4):281. doi: 10.1358/DOF.2021.46.4.3238324
Odoma VA, Nwabueze D, Alam B, Olaleye KT, Louise-Oluwasanmi O, Ballagan JS, et al. Zavegepant nasal spray for treatment of acute migraine: A systematic review. J Adv Med Med Res. 2023;35(16):69-77. doi: 10.9734/jammr/2023/v35i165090
Ashina H, Tfelt-Hansen P. Zavegepant for the acute treatment of migraine: Look before leaping. Nat Rev Neurol. 2023;19(6):329-30. doi: 10.1038/s41582-023-00803-4, PMID 37012363
Noor N, Angelette A, Lawson A, Patel A, Urits I, Viswanath O, et al. A comprehensive review of zavegepant as abortive treatment for migraine. Health Psychol Res. 2022;10(3):35506. doi: 10.52965/001c.35506, PMID 35774914
Scuteri D, Tarsitano A, Tonin P, Bagetta G, Corasaniti MT. Focus on zavegepant: The first intranasal third-generation gepant. Pain Manag. 2022;12(8):879-85. doi: 10.2217/pmt-2022-0054, PMID 36189708
Desnita R, Noviana E, Zai K, Saifullah Sulaiman TN. An up-to-date review: Microspheres as a new drug delivery system. Int J Appl Pharm. 2023;15(6):82-9. doi: 10.22159/Ijap.2023v15i6.49120
Pathak R, Dash RP, Misra M, Nivsarkar M. Role of mucoadhesive polymers in enhancing delivery of nimodipine microemulsion to brain via intranasal route. Acta Pharm Sin B. 2014;4(2):151-60. doi: 10.1016/j.apsb.2014.02.002, PMID 26579378
Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood-brain barrier (BBB) translocation: A way to deliver drugs to the brain? Int J Pharm. 2005;298(2):274-92. doi: 10.1016/j. ijpharm.2005.03.031, PMID 15896933
Sharma M, Sharma N, Sharma A. Rizatriptan benzoate loaded natural polysaccharide based microspheres for nasal drug delivery system. Int J Appl Pharm. 2018;10(5):261-9. doi: 10.22159/ijap.2018v10i5.27877
Chien YW, Chang SF. Intranasal drug delivery for systemic medications. Crit Rev Ther Drug Carrier Syst. 1987;4(2):67-194. PMID 3319200
Merkus FW, Verhoef JC, Schipper NG, Marttin E. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev. 1998;29(1-2):13-38. doi: 10.1016/s0169-409x(97)00059-8, PMID 10837578
Dahl R, Mygind N. Anatomy, physiology and function of the nasal cavities in health and disease. Adv Drug Deliv Rev. 1998;29(1-2):3-12. doi: 10.1016/s0169-409x(97)00058-6, PMID 10837577
Agu RU, Ugwoke MI. Drug Absorption Studies: In Situ, in Vitro and in Silico Model. Ch. 5. Berlin: Springer; 2007.
Pires A, Fortuna A, Alves G, Falcão A. Intranasal drug delivery: How, why and what for? J Pharm Pharm Sci. 2009;12(3):288-311. doi: 10.18433/j3nc79, PMID 20067706
Illum L. Nasal drug delivery--possibilities, problems and solutions. J Control Release. 2003;87(1-3):187-98. doi: 10.1016/s0168- 3659(02)00363-2, PMID 12618035
Stevens A, Lowe J. Human Histology. Philadelphia, PA: Mosby; 1997.
Ki DD, Drug Absorption Studies: Insitu, in Vitro and in Silico Models. Ch. 9. Berlin: Springer; 2007.
Riddle D, Washington N, Wilson CD. Drug delivery to the nasal and buccal cavities, anatomical and physiological considerations. In: Duchene D, editor. Buccal and Nasal Administration as an Alternative to Parental Administration. Paris: Editions De Sante Paris; 1992. p. 29-39.
Illum L. In: Mathiowitz E, Chickering DE, Lehr CM, editors. Bioadhesive Formulations for Nasal Peptide Delivery: Fundamentals, Novel Approaches and Development. New York: Marcel Dekker; 1999. p. 507-39.
Ingemann M, Frokjaer S, Hovgaard L, Brøndsted H. Peptide and protein drug delivery systems for non-parenteral routes of administration. In: Frokjaer S, Hovgaard L, editors. Pharmaceutical Formulation Development of Peptides and Proteins. Ch. 10. Philadelphia, PA: Taylor and Francis; 2000. p. 189.
Dhakar RC, Maurya1 SD, Tilak VK, Gupta AK. A review on factors affecting the design of nasal drug delivery system. Int J Drug Deliv. 2011;3:194-208.
Charlton S, Jones NS, Davis SS, Illum L. Distribution and clearance of bioadhesive formulations from the olfactory region in man: Effect of polymer type and nasal delivery device. Eur J Pharm Sci. 2007;30(3-4):295-302. doi: 10.1016/j.ejps.2006.11.018, PMID 17223022
Druce HM. Nasal physiology. Ear Nose Throat J. 1986;65(5):201-5. PMID 3522190
Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discov Today. 2002;7(18):967-75. doi: 10.1016/s1359- 6446(02)02452-2, PMID 12546871
Chauhan K, Gupta SK, Singhvi IJ, Chasta P. Review article- nasal drug delivery system. AJPSCR. 2011;1(3):55-66.
Nasare L, Niranjane K, Nagdevte A, Mohril S. Drug delivery system: An emerging approach for brain targeting. World J Pharm Pharm Sci. 2014;3(4):539-53.
Eller N, Kollenz CJ, Bauer P, Hitzenberger G. The duration of antidiuretic response of two desmopressin nasal sprays. Int J Clin Pharmacol Ther. 1998;36(9):494-500. PMID 9760011
Knoester PD, Jonker DM, Van Der Hoeven RT, Vermeij TA, Edelbroek PM, Brekelmans GJ, et al. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. Br J Clin Pharmacol. 2002;53(5):501-7. doi: 10.1046/j.1365-2125.2002.01588.x, PMID 11994056
Vidgren MT, Kublik H. Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev. 1998;29(1-2):157-77. doi: 10.1016/s0169-409x(97)00067-7, PMID 10837586
Electronic Medicines Compendium. Datapharm Communications Ltd; 2015. Available from: https://emc.medicines.org.uk
Ghori MU, Mahdi MH, Smith AM, Conway BR. Nasal drug delivery systems: An overview. Am J Pharmacol Sci. 2015;3(5):110-9.
Chaudhari A, Jadhav KR, Kadam VK. An over view: Microspheres as a nasal drug delivery system. Int J Pharm Sci Rev Res. 2010;5(1):8-17.
Imam SS. Nanoparticles: The future of drug delivery. Int J Curr Pharm Res. 2023 Nov;15(6):8-15. doi: 10.22159/ijcpr.2023v15i6.3076
Nataraj D, Reddy N. Chemical modifications of alginate and its derivatives. Int J Chem Res. 2020 Jan;4(1):1-17. doi: 10.22159/Ijcr.2020v4i1.98
Azhar M, Mishra A. Review of nanoemulgel for treatment of fungal infections. Int J Pharm Pharm Sci. 2024 Sep;16(9):8-17. doi: 10.22159/ Ijpps.2024v16i9.51528
Available from: https://www.accessdata.fda.gov
Available from: https://www.drug.com
Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230-41. doi: 10.1056/NEJMoa1813049, PMID 31800988
Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, Fan X, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014;83(11):958-66. doi: 10.1212/WNL.0000000000000771, PMID 25107879
Woodhead JL, Siler SQ, Howell BA, Watkins PB, Conway C. Comparing the liver safety profiles of 4 next-generation CGRP receptor antagonists to the hepatotoxic CGRP inhibitor telcagepant using quantitative systems toxicology modeling. Toxicol Sci. 2022;188(1):108-16. doi: 10.1093/toxsci/kfac051, PMID 35556143
Chan KY, Edvinsson L, Eftekhari S, Kimblad PO, Kane SA, Lynch J, et al. Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther. 2010;334(3):746-52. doi: 10.1124/ jpet.110.165993, PMID 20573757
Edvinsson L, Chan KY, Eftekhari S, Nilsson E, De Vries R, Säveland H, et al. Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries. Cephalalgia. 2010;30(10):1233-40. doi: 10.1177/0333102410362122, PMID 20855369
Deng X, Zhou L, Liang C, Shang X, Hui X, Liu W, et al. Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: Systematic review and network meta-analysis of randomised trials. J Headache Pain. 2024;25(1):16. doi: 10.1186/s10194-024-01723-4, PMID 38311738
Aschenbrenner DS. New nasal spray for migraine headaches. Am J Nurs. 2023;123(7):16. doi: 10.1097/01.NAJ.0000944900.69960.ee, PMID 37345774
Khan ZZ, Ahmed U, Shahzad F, Ali M, Tousif K, Ahmed U, et al. Safety and efficacy of zavegepant in treating migraine: A systematic review. Cureus. 2023;15(7):e41991. doi: 10.7759/cureus.41991, PMID 37593294
Porreca F, Navratilova E, Hirman J, Van Den Brink AM, Lipton RB, Dodick DW. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Cephalalgia. 2024;44(3). doi: 10.1177/03331024241238153, PMID 38477313
Palde C, Barot T, Chakraborthy GS, Patel LD. Peptide delivery via nasal route: Exploring recent developments and approaches. Int J Appl Pharm. 2024;16(4):46-56. doi: 10.22159/ijap.2024v16i4.50626
Published
How to Cite
Issue
Section
Copyright (c) 2025 MEENAKSHI SHARMA
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
